TG Therapeutics Sees Positive Financial Growth for BRIUMVI
TG Therapeutics, Inc. (NASDAQ: TGTX) is celebrating a significant achievement in the first quarter of 2025. The company announced that its BRIUMVI U.S. net revenue reached an impressive $119.7 million. This notable figure marks a remarkable growth of approximately 137% compared to the same period last year.
Raising Revenue Targets for 2025
In light of these results, TG Therapeutics has raised its full-year global net revenue target to around $575 million. The company has also revised the BRIUMVI U.S. net product revenue target upward to approximately $560 million, up from a prior estimate of $525 million. This optimistic outlook reflects the growing confidence from healthcare providers and patients in BRIUMVI as a leading treatment option for multiple sclerosis (MS).
CEO's Insight on BRIUMVI's Progress
Michael S. Weiss, the Chairman and CEO of TG Therapeutics, expressed pride in the company's achievements, emphasizing the positive feedback from both patients and clinicians. Mr. Weiss noted, "2025 is off to a strong start... Our performance in the first quarter demonstrates the growing confidence in our treatment. This progress underlines our long-term goal of making BRIUMVI the number one prescribed anti-CD20 therapy based on market share dynamics."
Commercialization and Innovation Developments
Besides its success in revenue, TG Therapeutics remains committed to innovating and expanding BRIUMVI’s capabilities. Currently, efforts are underway to streamline the treatment regimen, with ongoing trials for the subcutaneous administration of BRIUMVI. The company is also developing azercabtagene zapreleucel (azer-cel) aimed at treating progressive types of MS, reinforcing its dedication to enhancing treatment options for individuals affected by this condition.
Clinical Highlights and Study Results
TG Therapeutics presented compelling five-year data from its open-label extension study of the ULTIMATE I & II Phase 3 trials. The results revealed that an impressive 92% of patients treated with BRIUMVI showed no disability progression over five years. With an annualized relapse rate as low as 0.02 in the fifth year of treatment, the data further emphasized BRIUMVI’s safety profile, as no new safety signals emerged, and no cases of progressive multifocal leukoencephalopathy (PML) were reported.
Alternative Dosing Strategies
Further enhancing its commitment to patient care, TG Therapeutics is exploring alternative dosing strategies for BRIUMVI. During a recent presentation of the ENHANCE Phase 3b study, it was established that a single infusion of 600 mg on Day 1 was well-tolerated across various patient profiles. Additionally, rapid 30-minute infusions were also met with positive tolerance levels, showcasing the flexibility of the treatment.
Ongoing Trials and Financial Guidance
As part of its forward-looking strategy, TG Therapeutics has several clinical trials underway, including a Phase 1 trial for subcutaneous BRIUMVI and studies testing BRIUMVI in myasthenia gravis (MG). TG Therapeutics is also preparing to open trials evaluating azercel for conditions beyond MS.
The financial outlook remains bright, with total global revenue targets raised alongside a projected operating expense of approximately $300 million for the full year. The company is ensuring it has a robust financial foundation that supports its growth and innovation efforts.
Conclusion and Future Outlook
As TG Therapeutics continues to report significant growth in revenue, BRIUMVI is positioned strongly in the market for treating MS. With a relentless focus on innovation and patient experience, the company is setting the stage for further enhancements and strategies aimed at improving the lives of individuals living with MS. The excitement around the anticipated milestones and ongoing research illustrates a strong commitment to addressing the challenges faced by those affected by B-cell diseases.
Frequently Asked Questions
1. What is the primary focus of TG Therapeutics?
TG Therapeutics is focused on the development and commercialization of innovative treatments for B-cell diseases, particularly multiple sclerosis.
2. How much revenue did TG Therapeutics report for the first quarter of 2025?
The company reported a net revenue of $119.7 million for BRIUMVI in the U.S. during the first quarter of 2025.
3. What targets has TG Therapeutics raised for 2025?
The company raised its global net revenue target to approximately $575 million and the BRIUMVI U.S. net revenue target to roughly $560 million for 2025.
4. What is BRIUMVI and its significance?
BRIUMVI (ublituximab-xiiy) is a monoclonal antibody that targets CD20-expressing B-cells, offering a novel treatment option for relapsing forms of multiple sclerosis.
5. How is TG Therapeutics ensuring patient safety?
The company is conducting ongoing studies to monitor the safety and efficacy of BRIUMVI and is fully committed to observing and managing potential risks associated with treatment.
